Special Issue

Cancer Drugs Treatment and Toxicity

Message from the Guest Editor

Cancer drugs are commonly used to treat tumors. Unfortunately, the majority of cancer drugs (Doxorubicin, Ponatinib, Cisplatin, etc.) induce cardiomyopathy and muscle weakness as a side effect. The exact mechanisms of action of these drugs are far from clear: however, based on current research, it is suggested that increased oxidative stress, inflammation, mitochondrial dysfunction, and cell death are prominent mechanisms involved in the development and progression of these diseases. In this Special Issue, we invite both original and review articles that cover the current concepts of anticancer-drug-induced toxicity in the heart and muscle. These articles can be of a wider scope on topics such as oxidative stress, cell signaling, cell death, tissue remodeling, inflammation, and other relevant molecular mechanisms that are involved in anticancerdrug-induced cardiac and muscle toxicity. We will also welcome any current therapeutic strategies being investigated to attenuate anticancer-drug-induced side effects in the tissues.

Guest Editor

Prof. Dr. Dinender K. Singla

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA

Deadline for manuscript submissions

closed (31 March 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/56315

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

